Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients

• Published in: European journal of nuclear medicine Vol. 26; no. 6; pp. 625 - 632
• Main Authors: LORENTE, J. A, VALENZUELA, H, MOROTE, J, GELABERT, A
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.06.1999; Springer Nature B.V
• Subjects: Aged; Alkaline Phosphatase - blood; Biological and medical sciences; Biomarkers, Tumor - blood; Bone Neoplasms - diagnostic imaging; Bone Neoplasms - epidemiology; Bone Neoplasms - secondary; Humans; Logistic Models; Male; Medical sciences; Neoplasm Staging; Nephrology. Urinary tract diseases; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Radionuclide Imaging; ROC Curve; Tumors of the urinary system; Urinary tract. Prostate gland; Human; Alkaline phosphatase; Urinary system disease; Prostate disease; Enzyme; Stage classification; Prediction; Phosphoric monoester hydrolases; Esterases; Metastasis; Malignant tumor; Prostate specific antigen; Osteoarticular system; Receiver operating characteristic curves; Hydrolases; Serum; Diagnosis; Male genital diseases; Prostate

The aim of this study was to analyse the clinical utility of serum bone alkaline phosphatase (BAP) in addition to prostate-specific antigen (PSA) in the staging of newly diagnosed untreated prostate cancer patients. A prospective study was conducted, analysing serum BAP and PSA concentrations in 295...